Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors

Gabriella Pellegriti, Francesco Frasca, Concetto Regalbuto, Sebastiano Squatrito, Riccardo Vigneri, Gabriella Pellegriti, Francesco Frasca, Concetto Regalbuto, Sebastiano Squatrito, Riccardo Vigneri

Abstract

Background. In the last decades, thyroid cancer incidence has continuously and sharply increased all over the world. This review analyzes the possible reasons of this increase. Summary. Many experts believe that the increased incidence of thyroid cancer is apparent, because of the increased detection of small cancers in the preclinical stage. However, a true increase is also possible, as suggested by the observation that large tumors have also increased and gender differences and birth cohort effects are present. Moreover, thyroid cancer mortality, in spite of earlier diagnosis and better treatment, has not decreased but is rather increasing. Therefore, some environmental carcinogens in the industrialized lifestyle may have specifically affected the thyroid. Among potential carcinogens, the increased exposure to medical radiations is the most likely risk factor. Other factors specific for the thyroid like increased iodine intake and increased prevalence of chronic autoimmune thyroiditis cannot be excluded, while other factors like the increasing prevalence of obesity are not specific for the thyroid. Conclusions. The increased incidence of thyroid cancer is most likely due to a combination of an apparent increase due to more sensitive diagnostic procedures and of a true increase, a possible consequence of increased population exposure to radiation and to other still unrecognized carcinogens.

Figures

Figure 1
Figure 1
The trend in thyroid cancer incidence in the North American population from 1999 to 2008, subdivided by gender (a) and by disease stage at the time of diagnosis (b) (modified from Simard et al.) [11]. The trend in thyroid cancer incidence in the United States from 1980 to 2009 by histotype (c) (modified from Aschebrook-Kilfoy et al.) [20].

References

    1. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents. No. 160. Vol. 9. Lyon, France: IARC; 2007. (IARC Scientific Publications).
    1. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes and Control. 2009;20(5):525–531.
    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians. 2010;60(5):277–300.
    1. dal Maso L, Lise M, Zambon P, et al. Incidence of thyroid cancer in Italy, 1991–2005: time trends and age-period-cohort effects. Annals of Oncology. 2011;22(4):957–963.
    1. Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, Angelos P, Grogan RH. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Annals of Surgical Oncology. 2013
    1. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiology Biomarkers and Prevention. 2009;18(3):784–791.
    1. Kent WDT, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. Canadian Medical Association Journal. 2007;177(11):1357–1361.
    1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. Journal of the American Medical Association. 2006;295(18):2164–2167.
    1. Grodski S, Brown T, Sidhu S, et al. Increasing incidence of thyroid cancer is due to increased pathologic detection. Surgery. 2008;144(6):1038–1043.
    1. Rego-Iraeta A, Pérez-Méndez LF, Mantinan B, Garcia-Mayor RV. Time trends for thyroid cancer in northwestern spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid. 2009;19(4):333–340.
    1. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA: A Cancer Journal For Clinicians. 2012;62(2):118–128.
    1. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–3807.
    1. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid. 2011;21(2):125–134.
    1. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. Journal of the National Cancer Institute. 2009;101(19):1325–1329.
    1. Schlumberger M, Borget I, Nascimento C, Brassard M, Leboulleux S. Treatment and follow-up of low-risk patients with thyroid cancer. Nature Reviews Endocrinology. 2011;7(10):625–628.
    1. Ito Y, Miyauchi A. Is surgery necessary for papillary thyroid microcarcinomas? Nature Reviews Endocrinology. 2012;8(1):p. 9.
    1. Alexander EK, Larsen PR. Radioiodine for thyroid cancer—is less more? The New England Journal of Medicine. 2012;366(18):1732–1733.
    1. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. The New England Journal of Medicine. 2012;366(18):1663–1673.
    1. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. Journal of Clinical Endocrinology and Metabolism. 2004;89(8):3713–3720.
    1. Aschebrook-Kilfoy B, Grogan R, Ward M, Kaplan E, Devesa S. Follicular thyroid cancer incidence patterns in the United States, 1980–2009. Thyroid. 2013
    1. Mazzaferri EL. Management of a solitary thyroid nodule. The New England Journal of Medicine. 1993;328(8):553–559.
    1. Nilsson IL, Arnberg F, Zedenius J, Sundin A. Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/computed tomography: practical management algorithm. World Journal of Surgery. 2011;35(12):2691–2697.
    1. Yun M, Noh TW, Cho A, et al. Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. Journal of Clinical Endocrinology and Metabolism. 2010;95(7):3182–3188.
    1. Sprague BL, Warren Andersen S, Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes and Control. 2008;19(6):585–593.
    1. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer. 1985;56(3):531–538.
    1. Mazzaferri EL. Managing thyroid microcarcinomas. Yonsei Medical Journal. 2012;53(1):1–14.
    1. Haggar FA, Preen DB, Pereira G, Holman CD, Einarsdottir K. Cancer incidence and mortality trends in Australian adolescents and young adults, 1982–2007. BMC Cancer. 2012;12(1):p. 151.
    1. Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. British Journal of Cancer. 2001;85(9):1335–1339.
    1. Ellison LF, Wilkins K. Canadian trends in cancer prevalence. Health Reports. 2012;23(1):7–16.
    1. Wang Y, Wang W. Increasing incidence of thyroid cancer in shanghai, China, 1983–2007. Asia-Pacific Journal of Public Health. 2012
    1. Colonna M, Guizard AV, Schvartz C, et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000) European Journal of Cancer. 2007;43(5):891–900.
    1. Mathur A, Moses W, Rahbari R, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer. 2011;117(19):4390–4395.
    1. Romei C, Fugazzola L, Puxeddu E, et al. Modifications in the papillary thyroid cancer gene profile over the last 15 years. The Journal of Clinical Endocrinology & Metabolism. 2012;97(9):E1758–E1765.
    1. Zhu C, Zheng T, Kilfoy BA, et al. A birth cohort analysis of the incidence of papillary thyroid cancer in the united states, 1973–2004. Thyroid. 2009;19(10):1061–1066.
    1. Mettler FA, Jr., Bhargavan M, Thomadsen BR, et al. Nuclear Medicine Exposure in the United States, 2005–2007: preliminary results. Seminars in Nuclear Medicine. 2008;38(5):384–391.
    1. Mettler FA, Jr., Wiest PW, Locken JA, Kelsey CA. CT scanning: patterns of use and dose. Journal of Radiological Protection. 2000;20(4):353–359.
    1. Linton OW, Mettler FA. National conference on dose reduction in CT, with an emphasis on pediatric patients. American Journal of Roentgenology. 2003;181(2):321–329.
    1. Baker SR, Bhatti WA. The thyroid cancer epidemic: is it the dark side of the CT revolution? European Journal of Radiology. 2006;60(1):67–69.
    1. Williams D. Radiation carcinogenesis: lessons from Chernobyl. Oncogene. 2008;27(supplement 2):S9–S18.
    1. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. The Lancet. 2012;380(9840):499–4505.
    1. Mazonakis M, Tzedakis A, Damilakis J, Gourtsoyiannis N. Thyroid dose from common head and neck CT examinations in children: is there an excess risk for thyroid cancer induction? European Radiology. 2007;17(5):1352–1357.
    1. Berrington de González A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Archives of Internal Medicine. 2009;169(22):2071–2077.
    1. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiation Research. 1995;141(3):259–277.
    1. Richardson DB. Exposure to ionizing radiation in adulthood and thyroid cancer incidence. Epidemiology. 2009;20(2):181–187.
    1. Memon A, Godward S, Williams D, Siddique I, Al-Saleh K. Dental x-rays and the risk of thyroid cancer: a case-control study. Acta Oncologica. 2010;49(4):447–453.
    1. Ron E. Cancer risks from medical radiation. Health Physics. 2003;85(1):47–59.
    1. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. The New England Journal of Medicine. 1998;338(11):712–718.
    1. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109(10):1972–1979.
    1. Hieu TT, Russell AW, Cuneo R, et al. Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis. Endocrine-Related Cancer. 2012;19(5):645–655.
    1. Black P, Straaten A, Gutjahr P. Secondary thyroid carcinoma after treatment for childhood cancer. Medical and Pediatric Oncology. 1998;31(2):91–95.
    1. dal Maso L, Bosetti C, la Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes and Control. 2009;20(1):75–86.
    1. Pellegriti G, de Vathaire F, Scollo C, et al. Papillary thyroid cancer incidence in the volcanic area of sicily. Journal of the National Cancer Institute. 2009;101(22):1575–1583.
    1. Feldt-Rasmussen U. Iodine and cancer. Thyroid. 2001;11(5):483–486.
    1. Dijkstra B, Prichard RS, Lee A, et al. Changing patterns of thyroid carcinoma. Irish Journal of Medical Science. 2007;176(2):87–90.
    1. Harach HR, Escalante DA, Onativia A. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinologica. 1985;108(1):55–60.
    1. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 2009;94(5):1612–1617.
    1. Mazzaferri EL. Papillary and follicular thyroid cancer: selective therapy. Comprehensive Therapy. 1981;7(5):6–14.
    1. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. Journal of Clinical Endocrinology and Metabolism. 2008;93(3):809–814.
    1. Fiore E, Rago T, Provenzale MA, et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocrine-Related Cancer. 2009;16(4):1251–1260.
    1. Fiore E, Rago T, Provenzale MA, et al. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. Endocrine-Related Cancer. 2010;17(1):231–239.
    1. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? Journal of Surgical Research. 2008;150(1):49–52.
    1. Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity. Cell Biochemistry and Biophysics. 2009;55(2):55–79.
    1. Hegedus L. Clinical practice. The thyroid nodule. The New England Journal of Medicine. 2004;351(17):1764–1771.
    1. Marqusee E, Benson CB, Frates MC, et al. Usefulness of ultrasonography in the management of nodular thyroid disease. Annals of Internal Medicine. 2000;133(9):696–700.
    1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
    1. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-doppler features. Journal of Clinical Endocrinology and Metabolism. 2002;87(5):1941–1946.
    1. Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. Journal of Clinical Endocrinology and Metabolism. 2006;91(9):3411–3417.
    1. Mathai V, Idikula J, Fenn AS, Nair A. Do long-standing nodular goitres result in malignancies? Australian and New Zealand Journal of Surgery. 1994;64(3):180–182.
    1. Erbil Y, Barbaros U, Salmaslioğlu A, et al. Effect of thyroid gland volume in preoperative detection of suspected malignant thyroid nodules in a multinodular goiter. Archives of Surgery. 2008;143(6):558–563.
    1. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid. 2013;23(4):449–455.
    1. Vigneri P, Frasca F, Sciacca L, Frittitta L, Vigneri R. Obesity and cancer. Nutrition, Metabolism and Cardiovascular Diseases. 2006;16(1):1–7.
    1. Kitahara CM, Platz EA, Beane Freeman LE, et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiology Biomarkers and Prevention. 2011;20(3):464–472.
    1. Almquist M, Johansen D, Bjorge T, et al. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can) Cancer Causes Control. 2011;22(5):743–751.
    1. Rezzónico JN, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metabolic Syndrome and Related Disorders. 2009;7(4):375–380.
    1. Mijović T, How J, Pakdaman M, et al. Body mass index in the evaluation of thyroid cancer risk. Thyroid. 2009;19(5):467–472.
    1. Mack WJ, Preston-Martin S, Dal Maso L, et al. A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea. Cancer Causes and Control. 2003;14(8):773–785.
    1. Peterson E, De P, Nuttall R. BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review. PLoS One. 2012;7(1)e29177
    1. Kilfoy BA, Zhang Y, Park Y, et al. Dietary nitrate and nitrite and the risk of thyroid cancer in the NIH-AARP diet and health study. International Journal of Cancer. 2011;129(1):160–172.
    1. Ward MH, Kilfoy BA, Weyer PJ, Anderson KE, Folsom AR, Cerhan JR. Nitrate intake and the risk of thyroid cancer and thyroid disease. Epidemiology. 2010;21(3):389–395.
    1. Zhang Y, Guo GL, Han X, et al. Do polybrominated diphenyl ethers (PBDE) increase the risk of thyroid cancer? Bioscience Hypotheses. 2008;1(4):195–199.
    1. Christiani DC. Combating environmental causes of cancer. The New England Journal of Medicine. 2011;364(9):791–793.
    1. Arnbjornsson E, Arnbjornsson A, Olafsson A. Thyroid cancer incidence in relation to volcanic activity. Archives of Environmental Health. 1986;41(1):36–40.
    1. Kung TM, Ng WL, Gibson JB. Volcanoes and carcinoma of the thyroid: a possible association. Archives of Environmental Health. 1981;36(5):265–267.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner